Lobe Sciences (TSE:LOBE)
:LOBE
Want to see TSE:LOBE full AI Analyst Report?
LOBE Stock Chart & Stats
C$0.06
-C$0.01(-33.33%)
At close: 4:00 PM EST
C$0.06
-C$0.01(-33.33%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.18
Previous CloseN/A
Volume8.00K
Average Volume (3M)19.65K
Market Cap
C$36.38M
Enterprise ValueC$25.33M
Total Cash (Recent Filing)C$4.96M
Total Debt (Recent Filing)C$316.49K
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding269,487,120
10 Day Avg. Volume13,139
30 Day Avg. Volume19,648
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Reported LeverageModest reported leverage and very low absolute debt reduce near-term refinancing pressure and interest expense, giving management more flexibility to fund R&D and clinical programs. Low leverage preserves optionality to raise equity or secure partnership funding without heavy debt servicing burden.
Demonstrated Gross Profit In Earlier PeriodsPast periods with meaningful gross profit indicate the business can achieve positive unit economics under commercial conditions. If clinical programs translate to sustained revenue, the company has structural potential for attractive gross margins that support a durable path toward improving operating profitability.
Strategic Focus On Psychedelic TherapeuticsLobe's strategic focus on psychedelic-derived treatments targets a structural growth area in mental health and neurology. This positioning aligns with expanding clinical interest, potential regulatory pathways, and partnership/licensing opportunities that can create durable program value beyond short-term market cycles.
Bears Say
No Revenue; Persistent LossesZero trailing revenue combined with sizable and persistent operating and net losses means the company is not self-funding. Continued negative earnings increase reliance on external capital, raise execution risk for clinical development, and make the timeline to sustainable operations uncertain over the medium term.
Deep Negative Operating And Free Cash FlowSustained negative operating and free cash flow (~ -$3.4M TTM) indicate ongoing cash burn and limited internal funding capacity. This shortens runway for clinical programs, increases the likelihood of dilutive financings or program delays, and creates enduring funding risk absent material revenue or external financing.
Unstable/negative Equity HistoryPeriods of negative or volatile equity constrain access to non-dilutive capital and raise solvency concerns. Unstable equity complicates partnership, licensing, and debt negotiations, increasing the structural financing risk that can hamper long-term program execution and strategic optionality.
Lobe Sciences News
LOBE FAQ
What was Lobe Sciences’s price range in the past 12 months?
Lobe Sciences lowest stock price was C$0.03 and its highest was C$0.18 in the past 12 months.
What is Lobe Sciences’s market cap?
Lobe Sciences’s market cap is C$36.38M.
When is Lobe Sciences’s upcoming earnings report date?
Lobe Sciences’s upcoming earnings report date is Aug 05, 2026 which is in 76 days.
How were Lobe Sciences’s earnings last quarter?
Lobe Sciences released its earnings results on Apr 29, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Lobe Sciences overvalued?
According to Wall Street analysts Lobe Sciences’s price is currently Overvalued.
Does Lobe Sciences pay dividends?
Lobe Sciences does not currently pay dividends.
What is Lobe Sciences’s EPS estimate?
Lobe Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lobe Sciences have?
Lobe Sciences has 269,487,120 shares outstanding.
What happened to Lobe Sciences’s price movement after its last earnings report?
Lobe Sciences reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.636%.
Which hedge fund is a major shareholder of Lobe Sciences?
Currently, no hedge funds are holding shares in TSE:LOBE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lobe Sciences
Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.
Technical Analysis
MediPharm Labs
―
PharmaCielo
―
Nextleaf Solutions
―
Avicanna
―
Greenway Greenhouse Cannabis Corp.
―
Options Prices
Currently, No data available
---